TeselaGen Biotechnology Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
32
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
9
TeselaGen Biotechnology General Information
Description
Developer of a cloud-based informatics platform designed to accelerate the development of therapeutics, high-value chemicals, and agricultural products. The company uses artificial intelligence for rapid prototyping of recombinant molecules and machine-learning-driven design workflows, enabling clients to support the creation of DNA assemblies and combinatorial libraries.
Contact Information
Website
www.teselagen.comCorporate Office
- 3130 Alpine Road
- Suite 288 Number 166
- Portola Valley, CA 94028-7549
- United States
Corporate Office
- 3130 Alpine Road
- Suite 288 Number 166
- Portola Valley, CA 94028-7549
- United States
TeselaGen Biotechnology Timeline
TeselaGen Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Accelerator/Incubator | 20-Sep-2023 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 16-Feb-2023 | Completed | Generating Revenue | |||
| 7. Seed Round | 14-Oct-2020 | Completed | Generating Revenue | |||
| 6. Debt - PPP | 15-Apr-2020 | Completed | Generating Revenue | |||
| 5. Seed Round | 18-Jan-2018 | Completed | Generating Revenue | |||
| 4. Grant | 07-Feb-2017 | Completed | Generating Revenue | |||
| 3. Seed Round | 07-Apr-2014 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2014 | $1.2M | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | Completed | Startup |
TeselaGen Biotechnology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed 2 | ||||||||
| Seed 1 | ||||||||
| Seed | 2,000,000 | $0.001000 | $0.06 | $0.78 | $0.78 | 1x | $0.78 | 15.74% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
TeselaGen Biotechnology Comparisons
Industry
Financing
Details
TeselaGen Biotechnology Competitors (9)
One of TeselaGen Biotechnology’s 9 competitors is Kiro, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kiro | Venture Capital-Backed | Paris, France | ||||
| Alloy Therapeutics | Venture Capital-Backed | Waltham, MA | ||||
| Benchling | Venture Capital-Backed | San Francisco, CA | ||||
| Generate Biomedicines | Formerly VC-backed | Somerville, MA | ||||
| PrecisionLife | Venture Capital-Backed | Oxford, United Kingdom |
TeselaGen Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TeselaGen Biotechnology Patents
TeselaGen Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250046396-A1 | Method, apparatus, and computer-readable medium for optimized partitioning for assembly of nucleic acid sequences | Pending | 31-Jul-2023 | ||
| WO-2021217138-A1 | Method for efficiently optimizing a phenotype with a combination of a generative and a predictive model | Inactive | 24-Apr-2020 | ||
| US-11574703-B2 | Method, apparatus, and computer-readable medium for efficiently optimizing a phenotype with a combination of a generative and a predictive model | Active | 24-Apr-2020 | ||
| US-12217828-B2 | Method, apparatus, and computer-readable medium for efficiently optimizing a phenotype with a combination of a generative and a predictive model | Active | 24-Apr-2020 | ||
| US-20210257049-A1 | Method, apparatus, and computer-readable medium for efficiently optimizing a phenotype with a combination of a generative and a predictive model | Active | 24-Apr-2020 | G16B20/20 |
TeselaGen Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TeselaGen Biotechnology Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Endeavor Miami | Accelerator/Incubator | |||
| WeBoost VC | Venture Capital | Minority | ||
| Propel(x) | VC-Backed Company | Minority | ||
| Taram Capital | Venture Capital | Minority | ||
| Small Business Innovation Research and Small Business Technology Transfer Programs | Government |
TeselaGen Biotechnology FAQs
-
When was TeselaGen Biotechnology founded?
TeselaGen Biotechnology was founded in 2011.
-
Where is TeselaGen Biotechnology headquartered?
TeselaGen Biotechnology is headquartered in Portola Valley, CA.
-
What is the size of TeselaGen Biotechnology?
TeselaGen Biotechnology has 32 total employees.
-
What industry is TeselaGen Biotechnology in?
TeselaGen Biotechnology’s primary industry is Enterprise Systems (Healthcare).
-
Is TeselaGen Biotechnology a private or public company?
TeselaGen Biotechnology is a Private company.
-
What is TeselaGen Biotechnology’s current revenue?
The current revenue for TeselaGen Biotechnology is .
-
How much funding has TeselaGen Biotechnology raised over time?
TeselaGen Biotechnology has raised $9.4M.
-
Who are TeselaGen Biotechnology’s investors?
Endeavor Miami, WeBoost VC, Propel(x), Taram Capital, and Small Business Innovation Research and Small Business Technology Transfer Programs are 5 of 9 investors who have invested in TeselaGen Biotechnology.
-
Who are TeselaGen Biotechnology’s competitors?
Kiro, Alloy Therapeutics, Benchling, Generate Biomedicines, and PrecisionLife are some of the 9 competitors of TeselaGen Biotechnology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
